Suyeon Kim’s Post

Another interesting read on the richness of the ecosystem in greater Europe! Happy to see that those biotech have been adequately funded to bring them to the next value inflection point. With initial clinical data showing activity, no doubt that multiple partnerships including strategic ones will be be needed to bring more innovative differentiated drugs to patients. Always good to remember at that time that the what we aspire to become, achieve or create is the number 1 question in forging strong alliances!

We are happy to announce that our latest Blog Post on "Navigating the Complexities of Early Phase Immuno-Oncology Clinical Trials" is online. Imagine you're a small biotech company armed with a revolutionary new immunotherapy drug but facing a labyrinth of regulations and challenges in getting it to patients. You know this drug holds the potential to change lives, but navigating the complexities of early-phase trials is daunting. This blog post offers a comprehensive guide to help you navigate these trials, from understanding the unique requirements of immuno-oncology research to building strategic partnerships, managing budgets, and ensuring patient safety. We'll also explore the latest trends and innovations in the field and how a leading CRO like Kapadi can support you every step of the way. So, buckle up and get ready to unlock the transformative power of immuno-oncology trials! Read the full Blog here: https://lnkd.in/drf7GMiA #immunotherapy #biotech #clinicaltrials #patientcare #innovation #earlyphase #phaseI #phase1 #clinicalresearch

Where in Europe are innovations in drug development taking place❓   Drug Discovery World asked this question in its spring print edition. While many European countries that are considered leaders in drug discovery have a centralized hub around which this infrastructure is built, Switzerland boasts at least four separate yet complimentary centers of life science innovation:   #Basel is probably Switzerland’s most developed hub, though there is a significant investment in other cities like #Lausanne, #Zurich, and #Geneva. Switzerland has turned its size into a benefit, as each of these regional hubs can operate independently and yet cooperatively.   To learn more, check out the three articles on the topic by Drug Discovery World (register for free to read the full articles): 📰"Europe: Where is the drug discovery innovation?": https://lnkd.in/e-VhPQkv 📰 "Drug discovery hotspots: What is the secret to Switzerland’s success?" Part 1️⃣ on the regional hubs in Basel, Geneva/Lausanne, and Zurich: https://lnkd.in/eiWPCQqf Part 2️⃣ on how Swiss researchers advance new technology and tackle modern health challenges: https://lnkd.in/eMYeGmi5   #WhySwitzerland #SwitzerlandInnovation #Health #FutureOfHealth #LifeSciences #Biotech #Pharma Basel Area Business & Innovation Greater Geneva Bern area (GGBa) Greater Zurich Area Switzerland Innovation swisstech Swissnex Alessandro Mazzetti Christian Elias Schneider University of Zurich Actelion (now Janssen Pulmonary Hypertension), T3 Pharmaceuticals AG Roche Novartis Swiss Biotech Association Michael Altorfer Diana Spencer Marta V. Gehring Janet Joy Richard Hayhurst Corinne Ari.

📣We bring you the latest updates from Portugal's dynamic EIT Health InnoStars Community. 💡Basinov Institute from FHC Group – our new Network Partner, in collaboration with us and the Gulbenkian Institute for Molecular Medicine (GIMM), organizes the Basinnov Innovation Award 2024. This prestigious award seeks to honour groundbreaking research projects in oncology and immunotherapy with significant potential for application in the pharmaceutical industry. Apply by 4 October, 2024. For more information, click here: https://basinnov.com/ 🎙️ The digital age of health is not the future; it is already the present! There is a lot to say about this topic, but let’s start with the latest podcast in Expresso, where Marta Passadouro talks about health apps and digital therapies and how they are becoming as common as any medicine bought in the pharmacy. There is still a way to create a market for these progressive technologies in Portugal. Listen and learn more about how, together with our Partners, we’re working on it: https://lnkd.in/dYZFdBvu Interested to know more? Contact Marta Passadouro, the InnoStars Ecosystem Lead for Portugal. #CommunityUpdate #HiglightsFromPortugal #InnoStarsCommunity

A big thank you to Invest in Switzerland for resharing our recent interview about Basel being a world-class hub for innovation & entrepreneurship in the field of life sciences, biotech, and therapeutics. Why is that? 1️⃣ Amazing talent pool from academia and industry 2️⃣ Growing entrepreneurial culture and mindset 3️⃣ Universities stepping up their game and contributing to entrepreneurial development Want to know more? Follow-us, connect and get in touch! #innovation #entrepreneurship #startup #lifesciences

Proud to share with you today the release of our Group’s integrated annual report. In all the countries where Servier distributes its medicines, we have managed to make significant progress especially in the fight against #cancer and have continued to pursue advances in #cardiovascular and #metabolic #diseases, despite the economic and geopolitical challenges our industry faced in 2023. 🚀 Our efforts have been rewarded with market authorizations and have resulted in a second-place ranking in the annual PatientView report in #oncology. 🔬 This year was also marked by the opening of our new R&D Institute at Paris-Saclay, which signifies a shift towards innovation and collaboration. 🌱 Improving patient health becomes even more meaningful when we also care about the health of the planet. Our commitment to a positive societal impact is thus reflected in our #Servier2030 strategy, aiming for a substantial reduction in our carbon footprint. 🏆 We also celebrate our corporate culture, recognized by Top Employer Europe and Great Place To Work® certifications. A huge THANK YOU to our teams all over the world, whose #commitment and passion are at the heart of these successes. Together, we are moving towards a future where the health of patients and the planet is our priority.   Our integrated Annual Report is much more than a corporate document: it's an invitation to explore our mission, our values, our achievements and our vision. To know more : https://lnkd.in/e8TZXfPb #WeAreServier #Innovation #SustainableHealth #AnnualReport #ParisSaclay #RnD

India to be the largest R&D centre of BMS outside US. This further cements the rise of India as GCC hub where AI and ML based commercial analytics capability for clinical trials will be nurtured. Japanese pharma is still behind to catch up on this trend but more companies are taking cognizance slowly

🌍 𝑨𝑷𝑨𝑪 𝒕𝒐 𝒃𝒆 𝒕𝒉𝒆 𝒃𝒆𝒏𝒆𝒇𝒊𝒄𝒊𝒂𝒓𝒊𝒆𝒔 𝒇𝒖𝒕𝒖𝒓𝒆 𝒈𝒓𝒐𝒘𝒕𝒉  📈 Exciting developments are on the horizon for the CRO and clinical trial markets! According to new reports from Research and Markets, the global CRO market is projected to reach nearly $63 billion by 2030, growing at an annual rate of 7.39% from 2025 to 2030. Similarly, the clinical trial site network market is expected to grow at a comparable pace, hitting $13.76 billion globally by the end of the decade. Key drivers of growth: 🔬 Increased outsourcing and R&D expenditures 🌏 Rapid expansion in the Asia-Pacific region, which accounted for 46.4% of the global CRO market share in 2024 Asia-Pacific on the rise: The region is predicted to see the fastest growth in clinical trials between 2025 and 2030. Notably, China surged from 8% of global trial starts in 2013 to 29% in 2023, as highlighted in an IQVIA report. Therapeutic focus: In 2024, oncology dominated both markets: 30.66% of the CRO market 35.1% of the clinical trial market These trends point to a future where Asia-Pacific leads the way in clinical research, with oncology continuing to drive innovation and demand. My anecdotal evidence of this rings true with the report, when you think about the level of CROs in countries like Australia looking to capture overseas trials with government incentives to bolster their offerings. Let’s keep an eye on how this growth shapes the global clinical research landscape! 🚀 #ClinicalResearch #CRO #Oncology #AsiaPacific #Innovation #Growth

Poland's medical innovation advances despite ongoing challenges, report shows Polish medical innovation has seen improvements, yet significant challenges remain, according to the latest Access GAP data, with access to innovative therapies and diagnostics increasing. "Compared to the Visegrad countries, Poland has improved its score in terms of access to innovative therapies, but we are still behind the Czech Republic and Slovakia, and only Hungary has a worse score than us," Michał Byliniak, Director-General of The Employers' Union of Innovative Pharmaceutical Companies, told Euractiv. Innovations in oncology and rare diseases The Access GAP data reveals that Poland has made significant progress in the availability of innovative therapies for cancer and rare diseases. https://lnkd.in/eTAdKKRq #PublicHealth #Europe #StayInformed #StayEmpowered

How is the French biotech industry going? 🥖 With biotech recovering from a couple of challenging years, how is France doing these days? France has a lot going on for itself, with top biotech companies such as Sanofi and a strong ecosystem in rare disease solutions. While being one of the top biotech nations in Europe, France still faces many challenges, notably regarding the funding of its early-stage companies. 💼 Find out more in our latest article! ⬇️ https://lnkd.in/en2NUS4N #frenchbiotech #biotechindustry #biotechinnovation #biotechinvestment #rarediseases #biotechfunding #healthcare #biotechecosystem Amolyt Pharma | AstraZeneca | France Biotech